Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago

Mavacamten

Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Omnia (mavacamten) is used to treat adults who have obstructive hypertrophic cardiomyopathy (HCM) with symptoms, in New York Heart Association (NYHA) class II-III. It is given to improve functional capacity and symptoms.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Mavacamten is a reversible inhibitor that acts selectively on cardiac myosin, and it works through an allosteric site. It changes how many myosin heads can move into the "on actin" (power-generating) states. That lowers the chance of force-producing (systolic) cross-bridges forming, and also of residual (diastolic) ones. In HCM, two things are the main hallmarks of the mechanism: too many myosin actin cross-bridges, and a disturbed super-relaxed state. Mavacamten shifts the overall myosin population towards a super-relaxed state, which saves energy and can be recruited when needed. In HCM patients, this myosin inhibition reduces dynamic LVOT obstruction and improves cardiac filling pressures.

Pregnancy & Breastfeeding

Nobody knows whether Mavacamten passes into human or animal milk, what it does to a breastfed infant, or whether it changes milk production. When deciding what to do, the benefits of breastfeeding for the baby's development and health should be weighed against the mother's clinical need for Mavacamten. The possible side effects on the breastfed child, either from Mavacamten or from the mother's own underlying condition, should also be part of that decision.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: The recommended starting dose of Mavacamten is 5 mg by mouth once daily, and you can take it with or without food. As the dose is adjusted, the allowed doses are 2.5 mg, 5 mg, 10 mg or 15 mg once daily. The maximum recommended dose is 15 mg once daily. Patients may develop heart failure while taking Mavacamten. So the LVEF and the Valsalva left ventricular outflow tract (LVOT) gradient need to be checked regularly. This lets the doctor adjust the dose carefully to reach an appropriate target Valsalva LVOT gradient, while keeping LVEF at ≥50% and avoiding symptoms of heart failure. With daily dosing, it takes weeks to reach steady-state drug levels and the full effect. Genetic variation in metabolism and drug interactions can also cause large differences in how much of the medicine the body is exposed to. When starting or adjusting Mavacamten, look at the LVEF first. Then consider the Valsalva LVOT gradient and the patient's clinical status to decide the dose. The algorithms for Initiation and Maintenance give the right dosing and monitoring schedules, so follow them. If LVEF falls below 50% during treatment, interrupt Mavacamten. The algorithm for Interruption explains how to interrupt, restart or stop the medicine. If treatment was interrupted at 2.5 mg, either restart at 2.5 mg or discontinue permanently. Pediatric use: the safety and effectiveness of Mavacamten have not been established in pediatric patients.